| breast cancer - HR positive | ||||||
| es-BC - HR-positive - 1st line (L1) | la/mBC - HR positive | la/mBC - HR positive - (neo)adjuvant (NA) | la/mBC - HR-positive - 2nd line (L2) | la/mBC - HR positive - L2 - all population | la/mBC - HR positive - L2 - PIK3CA mutant | |
| phosphoinositide 3-kinase (PI3K) inhibitor | ||||||
| alpelisib based treatment | ||||||
| alpelisib plus fulvestrant | SOLAR-1 ... SOLAR-1 ... | |||||
| alpelisib plus letrozole | NEO-ORB ... NEO-ORB ... | |||||
| buparlisib based treatment | ||||||
| buparlisib plus fulvestrant | BELLE-2 ... | BELLE-3 | BELLE-2 ... | BELLE-2 ... | ||
| buparlisib plus letrozole | NEO-ORB ... | |||||
| taselisib based treatment | ||||||
| taselisib plus letrozole | LORELEI | |||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
